Cenedella.de

Patient Advocate since 1977.


Leave a comment

https://cenedella.de/ * Philip J. Cenedella IV * International Cannabis Consultant * Germany, Europe, USA and Canada markets * Medical Marijuana Patient Advocate since 1977 * Assist with Business Development, Licensing, Partnerships, and Strategic Direction.

Philip J. Cenedella IV

Bio

https://cenedella.de/
Philip J. Cenedella IV
International Cannabis Consultant
Medical Marijuana Patient Advocate since 1977.

First and foremost, Phil is a patient advocate for 4 decades having grown up in New York during the Rockefeller Drug Law years, then establishing himself in San Diego during the push for legalization there in the’ 90s.  Now he is situated in Germany during its historic transition into the leadership role of the European Cannabis industry.

Phil is uniquely qualified to help you establish your international business strategy having served as a Founding Board Member of the World Trade Center San Diego, a Lead Consultant for Deutsche Telekom, The California Trade and Investment Office, Deutsche Bank, IBM, San Diego Economic Development Board and many other entities.  He puts his years of business development, sales and distribution expertise to work for you in a highly professional, ethical and effective manner.

40 Years Experience:
Phil was born in Buffalo on the shores of the US/Canadian border, spent most of his life in San Diego overlooking the US/Mexico border, and now is living in Europe with its open borders and the opening of its legal Cannabis industry.

As a C-level business development executive in the technology and construction sectors, and a Founding Board of Director for the World Trade Center San Diego and San Diego Software Council, Phil has facilitated and closed sales and strategic partnerships worldwide.

Phil has also been Lead Consultant for the California Trade and Investment Office in Germany and catalyst for the CAL-IT Investment Forum in London.

He has served as a consultant for IBM, George Clinton, Deutsche Telekom, iSeeTV,  San Diego Convention Center, FINDLAW, Chaparral Computers and Networks, San Diego Economic Development Corporation, Deutsche Bank and many others in the Cannabis space (to remain confidential).

Phil is a USA citizen with an EU Work/Residence Permit.  He has exactly 40 years of firsthand knowledge of all aspects of our Industry and is a C-level International business development specialist who is highly professional yet very easy to work with.  He provides your firm with Strategic guidance and the ability to help you to increase your sales channels, distribution networks, and strategic partnerships.

Education:
1984, University of Dayton B.A. Psychology, Music minor-emphasis

Skill Level:
Sales 98%
Business Development 98%
International  trade 98%
Cannabis Industry 420%

Testimonials

 Who is Phil:
“Phil is an absolute professional. Flexible, hardworking and driven. His results were great and we highly recommend his services.” – BLF, NYC

“Phil has boundless enthusiasm and always applies 100% effort to all he does. Phil researched the US market for…. The USA became our best market by far, and I know that we would never have broken into that extremely tough market without Phil. His combination of broad based business knowledge, willingness to learn, team spirit and superb networking skills is very rare and extremely valuable. Always positive, he was a joy to work with. I thoroughly recommend him.” – GRB, UK

“Phil Cenedella has been my contact for several years and I have found him to be the consummate professional. He will always promptly return a call or provide me an answer to an inquiry. He is always “on-it” and truly treats a client as if they were part of his extended family. It’s very rare these days to find someone as dedicated to his business and his clients as Phil. Phil has all the characteristics of what I look for when I have occasion to be expanding my staff. He is honest to a fault, dedicated, sincere and is the paramount reason for my firm’s continuing…….” – DF ,USA

“Phil is the most personable, genuine, charismatic and effective business development manager I have had the pleasure to work with. He instills trust and confidence!”- JFL, EU

“Phil is family.” – George Clinton
Volunteer Positions:    Founder, Dayton and La Jolla Human Trafficking Accords, Founder, St. Vincent de Paul Christmas Caroling and Limo Party, Volunteer, Americans for Safe Access, Advisor, City of Hope – Dubai  Key accomplishments:  Assisted with the freeing from prison a child victim of human trafficking serving life without parole, initiated Goldman Sachs’ divestment of a human-trafficking related publication, assisted advocates on the frontlines in Dubai, Ohio, California and elsewhere.


Leave a comment

CANADA: ‘An awful lot of expertise’: Black market marijuana growers shouldn’t be shut out of legal market, says task force chair

‘An awful lot of expertise’: Black market marijuana growers shouldn’t be shut out of legal market, says task force chair

Adrian Wyld/ The Canadian Press”We didn’t want all those people excluded automatically from the possibility of participating in some way,” Anne McLellan, now a senior advisor at Bennett Jones LLP, said. Twitter Google+ LinkedIn Email Typo? MoreBlack market marijuana growers should be included in the legal market as they can provide valuable expertise as it evolves, Anne McLellan, chair of the federal government’s task force on legalization, said Monday.McLellan said the Task Force on Cannabis Legalization and Regulation, whose recommendations were broadly adopted in the government’s proposed Cannabis Act, concluded that previous criminal convictions during marijuana’s century of prohibition “shouldn’t be an automatic bar to them coming into the legal system.”“We didn’t want all those people excluded automatically from the possibility of participating in some way,” McLellan, now a senior advisor at Bennett Jones LLP, said in an interview with the Financial Post on the sidelines of a conference on cannabis regulation organized by the Ryerson University in Toronto.The task force’s November report called on the federal government to set up a system that allows various-sized producers to participate, including independent and craft growers.“There are lots of people who are producing now illegally — we talk about artisinal and craft producers — we want a diversity of producers,” McLellan said.“There’s an awful lot of expertise that’s outside the legal system right now and you wouldn’t want to lose all that.”RelatedMarketing restrictions to help small marijuana brands compete against deep-pocketed players: panel‘Turning green into green’: Payment startup aims to capitalize on banking void for marijuana companiesSome Canadian pot activists, including Marc and Jodie Emery, have expressed their disappointment that the draft legislation sets up a system that favours “big marijuana” because the federal government will strictly regulate and license who can produce the plant for sale. Under the current medical marijuana regime, Ottawa has handed out some 40 licences to produce, a small fraction of the number of applicants. However, McLellan points out that producing, manufacturing or selling pot are not the only economic opportunities in the coming multi-billion dollar legal marijuana market.“There are other ways for people to be involved in this industry. People focus on production or manufacturing, retail, and that’s all important, but that’s only the most visible part,” she said.“A lot is going to happen here and there are so many access points for people to be involved.”There are also a plethora of weed-related businesses —from fertilizers to security services to payment processors — carving niches in the space ahead of legalization expected in July 2018.Jodie and Marc Emery, owners of Cannabis Culture, at their store on Church Street in Toronto. They are quickly expanding their empire of dispensaries across Canada and are determined to do so regardless of whether the coming recreational market legalizes dispensaries like theirs. ” data-medium-file=”http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?quality=60&strip=all&w=300″ data-large-file=”http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?quality=60&strip=all&w=620″ class=”size-large wp-image-734308″ alt=”Tyler Anderson/National Post” src=”http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=620&quality=60&strip=all&h=389″ width=”620″ height=”389″ srcset=”http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=620&quality=60&strip=all&h=389 620w, http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=1240&quality=60&strip=all&h=778 1240w, http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=140&quality=60&strip=all&h=88 140w, http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg?w=300&quality=60&strip=all&h=188 300w, http://wpmedia.business.financialpost.com/2017/02/fp0204-gs-emergy-web.jpg” style=”max-width:100%;” />


Leave a comment

Here are the top podcasts of all time on CannaInsider.com

1.) Daniel Yazbeck – CEO of CDx, Test THC and CBD with this Handheld Device
     Listen on: CannaInsider.com   iTunes   (Episode #18)
2.) Nick Hice – Expert Grower Reveals His Secrets
     Listen on: CannaInsider.com   iTunes   (Episode #67)
3.) Isaac Dietrich – CEO of MassRoots, The Facebook of Cannabis
 Listen on: CannaInsider.com   iTunes   (Episode #23)
4.) Tripp Keber – Star of the Pot Barons of Colorado and CEO of Dixie Elixirs
 Listen on: CannaInsider.com   iTunes   (Episode #32)
5.) Yoni Ofir– The Sleek Plug N Plant Home Grow Solution for the Cannabis Connoisseur
 Listen on: CannaInsider.com  iTunes  (Episode #86)
7.) Dr. Lester Grinspoon – Harvard PhD says we are “brainwashed about cannabis”
 Listen on: CannaInsider.com   iTunes   (Episode #5)
8.) Steve DeAngelo – The Controversial Leader of the Cannabis Industry
 Listen on: CannaInsider.com   iTunes   (Episode #38)
BTW, here is how you subscribe to the podcast show on iTunes so you can set it and forget it.
Thank you for being an insider,
Matthew Kind
Get The CannaInsider App for your iPhone or Android Device and listen on the go


Leave a comment

Canadian pot companies see medical exports growing under Trudeau law

http://www.columbian.com/news/2017/apr/21/canadian-pot-companies-see-medical-exports-growing-under-trudeau-law/

By Josh Wingrove and Jen Skerritt, Bloomberg News

OTTAWA, Canada — Canada’s push to legalize recreational marijuana is rippling beyond its borders as companies move to boost exports of medicinal pot.

Prime Minister Justin Trudeau’s government unveiled its framework last week, quelling concern it would clamp down on export permits for existing medical-pot producers such as Canopy Growth Corp. and Aurora Cannabis Inc. Those companies, which have a head start on the legal recreational market, will continue to be allowed to export marijuana to countries such as Germany and Australia for medical and scientific use.

“It might not be so limited,” said Emily Larose, a partner with law firm Cassels Brock who specializes in cannabis regulation. Industry fears of onerous export restrictions have receded over the past year as bureaucrats typically approve any permit so long as the main requirements are met. “The way in which they’ve been granted so far seems to be more box-ticking.”

Companies in Canada, the second country and first major economy to unveil plans for legalization of recreational pot, have already secured investments and partnerships in countries where support for legalized medical marijuana is gaining ground. The global cannabis market may be worth $200 billion, with the medical market accounting for 25 percent to 50 percent of that, Daniel Pearlstein, a research analyst in Toronto at Eight Capital, said by email.

Canopy is already exporting to Brazil and Germany. Last year, the Smith Falls, Ontario-based company acquired pharmaceutical distributor MedCann GmbH, which has placed its cannabis strains in German pharmacies.

Bedrocan Canada Inc., a unit of Canopy, exported 10 kilograms of dried cannabis to Brazil to be used in a clinical study targeting epilepsy and pain management, according to a November statement.

Canada is emerging as a leader in public policy around marijuana and other countries will need its know-how as they shift toward making cannabis and cannabinoids part of standard medical treatment, said Chief Executive Officer Bruce Linton. That gives Canopy the chance to export product while the domestic industry makes that transition, and to set up production on the ground once it has, he said.

“All of these jurisdictions are contemplating or structuring a way in which production will occur in them,” Linton said by phone. “We are actually an exporter of public policy.”

That meshes with Trudeau’s view for the future of the Canadian economy: one pivoting from raw resource extraction toward white-collar jobs in the services sector.

“You’re going to develop know-how on how to make this stuff,” said Eileen McMahon, a partner at Torys LLP and chair of the law firm’s intellectual property and food and drug regulatory practices. “That know-how arguably could be used” outside Canada under the Trudeau law, she said, adding it’s possible “employees with that expertise could cross the border.”

Aurora intends to be a “significant” player in the Australian market and is looking at others as well, said Cam Battley, an executive vice president. The Cremona, Alberta-based company plans to use its capital and experience to export its product, and to set up in countries where marijuana may soon be legal, he said.

“Canada more broadly is a leader in the cannabis industry,” Battley said by phone. “That gives us a lot of potential power in other markets.”

Exports will be allowed “as long as they meet the strict regulatory requirements,” lawmaker Bill Blair, a former police chief and Trudeau’s point man on pot legalization, said in an interview. He brushed aside questions about whether the government wants to encourage companies to be exporters. “We want to make sure there is a viable industry capable of supplying that well-regulated retail market” domestically in Canada.

The government has to issue export permits repeatedly, and could clamp down, change guidelines or slow its issuing of permits if it wanted to cool the market.

In a notice posted last year, Canada said it “does not support facilitating a regime premised on servicing global demand given the associated public health, safety and security risks” and that export “would be permitted under very limited circumstances.” Fears stoked in industry by that notice have since eased, Larose said.

Aurora secured a 19.9 percent stake last month in Cann Group, the first Australian company to be licensed for research and cultivation of medical cannabis for human use.

Aphria Inc., based in Leamington, Ontario, is investing $25 million in a dispensing operation in Florida, the company said April 4. Aphria’s U.S. expansion strategy is to target key states that have approved medical marijuana, according to the statement.

Canada’s legalization effort may violate its obligations under international law, Steven Hoffman, director of the University of Ottawa’s Global Strategy Lab, wrote in a Globe and Mail editorial this week. “Unless we change our constitution, Canada cannot legally legalize cannabis without either renegotiating the U.N. treaties, obtaining special exceptions, finding creative workarounds, or withdrawing from them,” he wrote.

The government believes its restrictions on production or sale outside its strictly regulated regime, as well as restrictions on some exports and use by minors, keeps it onside, Blair said.

“We believe this enables us to uphold and maintain our obligations under those treaties,” he said, speaking in an interview after Justice Minister Jody Wilson-Raybould referred questions on the matter to Blair.


Leave a comment

Why is Big Pharma fighting Medical Marijuana so hard? A new report published in Health Affairs found that if all states had legalized medical cannabis in 2014, Medicaid could have saved $1 billion in spending on prescriptions…could be one of the reasons.

If all states had had a medical marijuana law in 2014, we estimated that total savings for fee-for-service Medicaid could have been $1.01 billion. 

I write about retail and cannabis.

A new report published in Health Affairs found that if all states had legalized medical marijuana in 2014, Medicaid could have saved $1 billion in spending on prescriptions.

The study by Ashley C. Bradford and W. David Bradford examined whether states with medical marijuana laws saw changes for prescription drugs among Medicare Part D enrollees. Their analysis covered data between 2007 to 2014 and found that patients did indeed substitute medical marijuana for FDA-approved prescription drugs in these states.

“Total estimated Medicaid savings associated with these laws ranged from $260.8 million in 2007 to $475.8 million in 2014,” the study states. Granted this is only 2% of the total Medicaid drug spending for 2014, which was $23.9 billion, but it is still substantial savings. The Bradfords estimate that if all states had legalized medical marijuana in 2014, “The national savings for fee-for-service Medicaid would have been approximately $1.01 billion.” This works out to an average per state savings of $19.825 million a year.

However, only 26% of Medicaid customers are enrolled in the fee-for-service program. The study notes that if they applied their analysis equally to Medicaid managed care, then the savings could jump to a whopping $3.89 billion. Again, this is only if all states legalized medical marijuana.

Granted the savings are mostly enjoyed by private insurers that run the plans, but the Bradfords suggest that state governments could reduce their payments to the insurers as prescription drug costs fall.

The study only looked at conditions that could be treated with medical marijuana and the prescription drugs that would be affected. This included anxiety, depression, glaucoma, nausea, pain, psychosis, seizures, sleep disorders and spasticity. According to the study, “the differences ranged from a 42% reduction for prescriptions used to treat nausea to a 15% reduction for spasticity.” The Bradfords also found a 13% decline in depression drug prescriptions, a 12% drop in psychosis drug prescriptions and an 11% slide in pain drugs. There was no significant drop in drugs used for anxiety, glaucoma or sleep disorders.

The Bradfords noted that their study was challenged by the fact that states keep changing their medical marijuana laws and expanding approved conditions. Furthermore, they only had data available from fee-for-service Medicaid prescriptions. Managed care patient data was inconsistent. Thus, their findings are really lower than what the true savings could really be, suggesting it could be in the billions.


Leave a comment

Import & Export of Medicinal Cannabis Products…to and from Canada.

Blue Diamond Ventures, Inc. a Colorado Corporation ( OTC PINK : BLDV ) today announces that the company has entered into a Joint Development Agreement with Alternative Medical Solutions Inc., to import & export Targeted Medicinal Cannabis Products and Advanced Cannabis Technologies, to and from Canada.

The recent CannaTech Conference in Israel provided the forum to secure the initial agreements required to pursue this effort. Blue Diamond Ventures is not alone; Jeffrey Friedland, noted author and cannabis thought leader, has announced that CannRX is taking a similar approach by partnering to bring Israeli Technologies into the U.S. and other countries. https://israel-cannabis.com/2017/03/22/cannrx-icanisrael-ican-sleep/

Alternative Medical Solutions (AMS) is in the final stage to gain a full license to grow, market and sell medicinal cannabis products via Health Canada. BLDV has been working with AMS over the last year to finalize funding for its Fifty (50) thousand square foot cultivation facility. “There has been recognition, by the Canadian Government, for the need to allow import and export in this industry,” says Joshua B. Alper, CEO of BLDV. “This new effort will ensure that AMS, when licensed, will be a Global Project, with their products being available worldwide and with access to the ingredients and technology that will continue to make AMS a leader in the Canadian market.”

“We are excited to launch this effort with BLDV,” said Joseph Groleau, VP Business Development for AMS. “With the specialized products and technologies coming into Canada from Israel, and access to global markets with our finished products, we see this as a separate profit center that could even outgrow our efforts in cultivation.”

Canada will be the home to the new joint venture, and the first market focus will be to bring Israeli Cannabis products and technology to Canada. “AMS is the perfect partner for this project,” said Joshua B. Alper, CEO of Blue Diamond Ventures, Inc. “They have a great team at AMS that has been challenged by the ever-shifting landscape of compliance and financial requirements, this project can create significant revenue even prior to AMS receiving the cultivation and manufacturing licenses from Health Canada.” BLDV senior project manager, Jonathan B. Alper, who is fluent in Hebrew and has been involved in import and export of products from Israel, to Canada, and the U.S. for over 25 years, will manage the effort in cooperation with a team of license and compliance experts in Canada.

In other news:

BLDV has filed its Annual Report on the OTC Markets and has recently secured employment contracts with all key personnel for common stock, without the need to raise authorized common stock levels, or issue special warrants, options and/or preferred stock.

About BLDV:

Blue Diamond Ventures, Inc. seeks to partner with individuals and companies that share a common synergy, mission, and vision to enable products/services that are produced, delivered and consumed utilizing fewer natural resources, providing a sustainable alternative to traditional products on the market today. As a diversified customer centric Management / Holding Company; Blue Diamond Ventures, Inc. seeks opportunities in various markets and is driven by critical thinking and the scientific method.

About AMS:

Alternative Medical Solutions (“AMS”) is in the process of becoming a Licensed Producer of Medical Marijuana in Canada and is led by a highly passionate team dedicated to being at the forefront of the growing Medical Marijuana industry.

Safe Harbor:

This press release contains forward-looking statements. Such forward-looking statements are subject to several risks, assumptions, and uncertainties that could cause the Company’s actual results to differ materially from those projected in such statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly revise any forward-looking statements.


Leave a comment

Germany Medical Marijuana / Cannabis Application to Grow – German partner wanted – for Medizinische Ausrüstungen, Arzneimittel und Körperpflegeprodukte 2017/S 070-131987

If you a German organization interested in partnering with one of the world’s leading producers of pharmaceutical grade cannabis, please send a confidential email to phil@cenedella.de  for immediate consideration as a strategic and financial partner in the German BfArM application titled:

Medizinische Ausrüstungen, Arzneimittel und Körperpflegeprodukte

2017/S 070-131987